A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including World <a target=_blank ...

The drawbacks of retinoids involve the potential for irritancy, which can be concentration- and vehicle-dependent.

Sanofi says that its experimental drug amlitelimab ... At the American Academy of Dermatology (AAD) congress in San Diego, data from STEAM-AD showed that amlitelimab achieved sustained improvement ...

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: ...

Sanofi made the biggest leap up the corporate reputation in dermatology rankings ... Companies with new biologic skin-condition products such as Novartis and Janssen, or those expanding their ...

Report Ocean has published a new report on the Facial Injectable Market, delivering an extensive analysis of key factors such as market restraints, drivers, and opportunities. The report offers a ...

Sanofi, Abbott, and Medtronic. G.A.F. is President and CEO of Kinexum, which advises multiple health product companies in the fields of metabolism, cardiology, oncology, and dermatology.

Sanofi gets rated buy today ... as it has been driving revenue from multiple products rather than a single magic drug.

Regeneron and Sanofi's Dupixent sBLA for treating chronic spontaneous urticaria in patients 12+ gets FDA review, with a ...

The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to improve drug development by speeding up clinical trial recruitment.